Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12502357rdf:typepubmed:Citationlld:pubmed
pubmed-article:12502357lifeskim:mentionsumls-concept:C0205148lld:lifeskim
pubmed-article:12502357lifeskim:mentionsumls-concept:C0681842lld:lifeskim
pubmed-article:12502357lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:12502357lifeskim:mentionsumls-concept:C0282354lld:lifeskim
pubmed-article:12502357pubmed:issue1lld:pubmed
pubmed-article:12502357pubmed:dateCreated2002-12-27lld:pubmed
pubmed-article:12502357pubmed:abstractTextMolecular descriptors calculated by the VolSurf program have been extensively used to model pharmacokinetic properties, e.g., passive permeability through the gastrointestinal tract or through the blood-brain barrier. These descriptors quantify steric, hydrophobic, and hydrogen bond interactions between model compounds and different environments. Since these interactions are the same as those involved in the ligand-receptor binding, VolSurf descriptors could potentially be relevant in modeling this process as well. We obtained a significant model (r(2) = 0.85, q(2) = 0.75) using VolSurf descriptors derived from the ligand, the protein, and the ligand-protein complex for a diverse set of 38 structures previously used in the VALIDATE (ref 23) training set. Furthermore, a statistically significant model (r(2) = 0.94, q(2) = 0.89) was obtained using the same type of descriptors for a homogeneous set of glycogen phosphorylase inhibitors (ref 25). Using the VolSurf computational framework, both ligand-receptor binding and the ligand's pharmacokinetic behavior can be modeled simultaneously during the preclinical aspects of drug discovery.lld:pubmed
pubmed-article:12502357pubmed:languageenglld:pubmed
pubmed-article:12502357pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12502357pubmed:citationSubsetIMlld:pubmed
pubmed-article:12502357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12502357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12502357pubmed:statusMEDLINElld:pubmed
pubmed-article:12502357pubmed:monthJanlld:pubmed
pubmed-article:12502357pubmed:issn0022-2623lld:pubmed
pubmed-article:12502357pubmed:authorpubmed-author:UngellAnna-Le...lld:pubmed
pubmed-article:12502357pubmed:authorpubmed-author:CrucianiGabri...lld:pubmed
pubmed-article:12502357pubmed:authorpubmed-author:PastorManuelMlld:pubmed
pubmed-article:12502357pubmed:authorpubmed-author:ZamoraIsmaelIlld:pubmed
pubmed-article:12502357pubmed:authorpubmed-author:OpreaTudorTlld:pubmed
pubmed-article:12502357pubmed:issnTypePrintlld:pubmed
pubmed-article:12502357pubmed:day2lld:pubmed
pubmed-article:12502357pubmed:volume46lld:pubmed
pubmed-article:12502357pubmed:ownerNLMlld:pubmed
pubmed-article:12502357pubmed:authorsCompleteYlld:pubmed
pubmed-article:12502357pubmed:pagination25-33lld:pubmed
pubmed-article:12502357pubmed:meshHeadingpubmed-meshheading:12502357...lld:pubmed
pubmed-article:12502357pubmed:meshHeadingpubmed-meshheading:12502357...lld:pubmed
pubmed-article:12502357pubmed:meshHeadingpubmed-meshheading:12502357...lld:pubmed
pubmed-article:12502357pubmed:meshHeadingpubmed-meshheading:12502357...lld:pubmed
pubmed-article:12502357pubmed:meshHeadingpubmed-meshheading:12502357...lld:pubmed
pubmed-article:12502357pubmed:meshHeadingpubmed-meshheading:12502357...lld:pubmed
pubmed-article:12502357pubmed:meshHeadingpubmed-meshheading:12502357...lld:pubmed
pubmed-article:12502357pubmed:year2003lld:pubmed
pubmed-article:12502357pubmed:articleTitleSurface descriptors for protein-ligand affinity prediction.lld:pubmed
pubmed-article:12502357pubmed:affiliationDMPK & Bioanalytical Chemistry, AstraZeneca R & D Mölndal, S-431 83 Mölndal, Sweden. ismael.zamora@telefonica.netlld:pubmed
pubmed-article:12502357pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:12502357lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12502357lld:pubmed